Prandin, NovoNorm (repaglinide) is a small molecule pharmaceutical. Repaglinide was first approved as Prandin on 1997-12-22. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against ATP-binding cassette sub-family C member 8.
|Trade Name||NovoNorm, Prandin|
|Indication||type 2 diabetes mellitus|
|Drug Class||Antidiabetic, SGLT2 inhibitors, not phlorozin derivatives|